Letrozole , 98% , 112809-51-5

Synonym(s):
4,4ʹ-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile, 1-( bis-(4-Cyanophenyl)methyl)-1,2,4-triazole;4,4′-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile;Aromatase Inhibitor II, Letrozole - CAS 112809-51-5 - Calbiochem;Letrozole

CAS NO.：112809-51-5

Empirical Formula: C17H11N5

Molecular Weight: 285.3

MDL number: MFCD00866241

EINECS: 675-034-8

PRODUCT Properties

• Melting point: 181-183°C
• Boiling point: 563.5±60.0 °C(Predicted)
• Density: 1.21±0.1 g/cm3(Predicted)
• storage temp.: 2-8°C
• solubility: DMSO: >50mg/mL
• pka: 1.52±0.11(Predicted)
• form: White powder
• color: white to off-white
• Merck: 14,5450
• InChI: InChI=1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
• InChIKey: HPJKCIUCZWXJDR-UHFFFAOYSA-N
• SMILES: C(C1=CC=C(C=C1)C#N)(C1=CC=C(C=C1)C#N)N1C=NC=N1

Description and Uses

Letrozole, also known as Femara, is an orally active aromatase inhibitor that works by competitively inhibiting aromatase. This inhibition prevents the conversion of androgens to estrogen (estrogen stimulates breast tissues and breast cancer reoccurrence) and gonadal steroidogenesis. It can be used for the treatment of breast cancer that is hormonally-responsive or has an unknown receptor status in postmenopausal women. Besides this, Letrozole also has some off-label use such as ovarian stimulation, pretreatment of termination of pregnancy, treatment of gynecomastia, treatment of endometriosis, and promoting spermatogenesis for male patients of nonobstructive azoospermia.

A nonsteroidal aromatase inhibitor structurally related to Fadrozole. Antineoplastic

Safety

• Symbol(GHS): GHS08
• Signal word: Warning
• Hazard statements: H361fd-H373
• Precautionary statements: P202-P260-P280-P308+P313-P405-P501
• Hazard Codes: Xi
• Risk Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• RTECS: DI4957000
• HS Code: 2933997500